Asset 10.png

Ron Firestein

Hudson Institute of Medical Research
Clayton, Australia



CBTN Participants


Children's Cancer Foundation

About this


Major advances have been achieved in the discovery and application of targeted therapy for adult solid tumors, but therapeutic options for pediatric solid tumors have been limited. Current precision medicine programs focus on genomic sequencing, identifying the genes in a tumor’s DNA, to identify mutations, or changes, that may predict patients’ responses to targeted therapies. Unfortunately, currently 10% or fewer cancer patients have mutations that can be targeted and only 50% of those patients respond to therapy. This shows a need to identify new targets for treatment that improve treatment efficacy and limit the side effects of standard chemotherapy and radiation therapy. This project focuses on developing and utilizing individual patients’ tumor cells to identify new therapeutic targets and repurpose existing targets using new technologies, particularly for patients with high risk solid tumor (sarcomas, brain malignancies, refractory Wilms tumour, and neuroblastoma). Researchers will access the unique and comprehensive dataset provided by the Pediatric Brain Tumor Atlas to complete this work, and the Children’s Brain Tumor Network will also provide the computational and technological support necessary for this high level analysis.

Ask The


Ask the scientists

What are the goals of this project?

Researchers will complete comprehensive molecular analysis on pediatric brain cancers and perform a screen to identify therapeutic targets.

What is the impact of this project?

Treatment efficacy for many forms of pediatric brain tumors is low and often leaves patients with lasting side effects. A more comprehensive understanding of each cancer type could lead researchers to novel therapies. Screening for therapeutics targets will potentially identify target therapeutic opportunities.

Why is the CBTN request important to this project?

In addition to access the comprehensive data provided by the Pediatric Brain Tumor Atlas, CBTN will also provide this project with the necessary computational support to complete this complex analysis.

Specimen Data

The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas and by leading the computational efforts for the brain cancer analysis.

Explore the data in these informatics portals


Meet The


Annie Huang, Hospital for Sick Children, Canada

  • Perform Assay for Transposase Accessible Chromatic with high-throughput sequencing (ATAC-seq) to chart chromatin accessibility at a genome-wide scale

Roger Daly, Monash University, Australia

  • Perform global phospho-proteomic profiling to identify signatures of activated oncogenic pathways and kinases on patient tumour models grown in culture conditions.

Other team members:

  • Claire Sun, Hudson Institute of Medical Research, Australia
  • Daniel Gough, Hudson Institute of Medical Research, Australia
  • Duncan Crombie, Hudson Institute of Medical Research, Australia